HeberPAG® y carcinoma basocelular periocular: serie de casos con evolución a 5 años en La Habana, Cuba

Yemila Estévez Álvarez; Yanisel Jiménez Barbán; Emery Lazo Morales; Yusimy Davas Andrade; Arturo Iván Pérez Pacheco

doi:10.70313/2718.7446.v16.n02.227

Authors

Yemila Estévez Álvarez Cirugía Plástica Ocular, Servicio de Oftalmología, Hospital General Docente Dr. Enrique Cabrera, Habana, Cuba
Yanisel Jiménez Barbán Cirugía Plástica Ocular, Servicio de Oftalmología, Hospital General Docente Dr. Enrique Cabrera, Habana, Cuba
Emery Lazo Morales Servicio de Oftalmología, Hospital General Docente Dr. Enrique Cabrera, Habana. Cuba
Yusimy Davas Andrade Servicio de Dermatología, Hospital General Docente Dr. Enrique Cabrera, Habana, Cuba
Arturo Iván Pérez Pacheco Departamento de Investigación, Servicio de Oftalmología, Hospital General Docente Dr. Enrique Cabrera, Habana, Cuba

DOI:

https://doi.org/10.70313/2718.7446.v16.n02.227

Keywords:

HeberPAG™, Basal cell carcinoma, interferon, ocular plastic surgery, skin neoplasm

Abstract

Objective: To describe the experience of the use of HeberPAG® in patients diagnosed with periocular basal cell carcinoma.

Materials and methods: A retrospective, single-center case series study was conducted in the Department of Ocular Plastic Surgery, including patients treated with HeberPAG®, diagnosed with periocular basal cell carcinoma and with 5 years of evolution.

Results: All treated patients corresponded to white skin color. The skin phototype according to the Fitzpatrick scale present in these patients was type II with 6 cases and phototype III with 3 cases. Of the 9 patients studied, 5 patients presented periocular basal cell carcinoma in the lower eyelid; in upper eyelid, external canthus, internal canthus, and eyebrow, 1 patient respectively.

Conclusion: The experience of using HeberPAG® in 9 patients diagnosed with periocular basal cell carcinoma was demonstrated, with satisfactory results in primary and recurrent tumors. This constitutes an additional therapy for the treatment of basal cell carcinoma with a stable behavior at 5 years, as well as a complete remission of 99%.

Downloads

Download data is not yet available.

References

Fernandez-Martori M, Bello-Rivero I, Duncan-Roberts Y. Treatment of basal cell carcinoma with interferons alpha-2b and gamma in primary care. MEDICC Rev 2018; 20: 11.

Gracia Medina EA. Registro Nacional de Cáncer, información necesaria. Registro Nacional de Cáncer. Rev Cubana Oncol 2020;18: e66. Disponible en: https://revoncologia.sld.cu/index.php/onc/article/download/66/35.

Marzuka AG, Book SE. Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management. Yale J Biol Med 2015; 88: 167-179.

Trakatelli M, Morton C, BCC subcommittee of the Guidelines Committee of the European Dermatology Forum et al. Update of the European guidelines for basal carcinoma management. Eur J Dermatol 2014; 24: 312-329.

García Martín E, Fernández Tirado FJ. Tendencias en el tratamiento de los carcinomas basocelulares perioculares. Arch Soc Esp Oftalmol 2010; 85: 261-262.

García Vega Y, García-García I, Collazo-Caballero SE et al. Pharmacokinectic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial. BMC Pharmacol Toxicol 2012; 13:20.

Lang BM, Grabbe S. Diagnostik und Therapie des Basalzellkarzinoms [Diagnosis and treatment of basal cell carcinoma : a question of the risk of recurrence]. Hautarzt 2020; 71: 580-587.

Vázquez-Blomquist D, Fernández JR, Miranda J et al. Selection of reference genes for use in quantitative reverse transcription PCR assays when using interferons in U87MG. Mol Biol Rep 2012; 39: 11167-11175.

García-Vega Y, García-García I, Collazo-Caballero SE et al. Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial. BMC Pharmacol Toxicol 2012; 13:20.

Basset-Seguin N, Herms F. Update in the management of basal cell carcinoma. Acta Derm Venereol 2020; 100: adv00140.

Kim DP, Kus KJB, Ruiz E. Basal cell carcinoma review. Hematol Oncol Clin North Am 2019; 33: 13-24.

Altun E, Schwartzman G, Cartron AM, Khachemoune A. Beyond Mohs surgery and excisions: a focused review of treatment options for subtypes of basal cell carcinoma. Dermatol Ther 2020; 34: e14476.

Gupta N, Ruiz ES. Current perspectives in the treatment of locally advanced basal cell carcinoma. Drug Des Devel Ther 2022; 16: 183190.

Tanese K. Diagnosis and management of basal cell carcinoma. Curr Treat Options Oncol 2019; 20: 13.

Herms F, Basset-Seguin N. Emerging drugs for the treatment of basal cell carcinoma. Expert Opin Emerg Drugs 2021; 26: 17-26.

Monroe M, Kakarala K. Management of advanced basal cell carcinoma of the head and neck. Otolaryngol Clin North Am 2021; 54: 271-280.

Bertino G, Muir T, The InspECT Bcc Working Group et al. Treatment of basal cell carcinoma with electrochemotherapy: insights from the InspECT registry (2008-2019). Curr Oncol 2022; 29: 5324-5337.

Zhang H, Ping XL, Lee PK et al. Role of PTCH and p53 genes in early-onset basal cell carcinoma. Am J Pathol 2001; 158: 381-385.

Yarian N, Ailyn del Carmen C, Ledisleydy C. Aplicación del HeberPAG en carcinoma basocelular periocular: primeras experiencias en la provincia de Villa Clara. Acta Médica del Centro 2015; 9 No.4. 2015. Disponible en: https://revactamedicacentro.sld.cu/index.php/amc/article/view/299.

García Martín E, Fernández Tirado FJ. Tendencias en el tratamiento de los carcinomas basocelulares perioculares. Arch Soc Esp Oftalmol 2010, 85: 261-262.

American Academy of Ophthalmology. Orbit, eyelids and lacrimal system. San Franciso: American Academy of Ophthalmology, 2018 (Basic and clinical science course).

Ramírez K, Gómez C, Díaz M. Láser de dióxido de carbono en oculoplastia. Ríos M, Capote A, Hernández J, Eguías F, Padilla C (eds.). Oftalmología: criterios y tendencias actuales. La Habana: Editorial Ciencias Médicas, 2009, p. 27-34.

Gallagher RP, Hill GB, Bajdik CD et al. Sunlight exposure, pigmentary factors, and risk of nonmelanocytic skin cancer. I. Basal cell carcinoma. Arch Dermatol 1995; 131: 157-163.

Pannello G, Devesa S, Gail M. Association of surface ultraviolet B radiation levels with melanoma and nonmelanoma skin cancer in United States blacks. Cancer Epidemiol Biomarkers Prev 2000; 9: 291-297.